Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...
Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...
As Ozempic use rises, society’s obsession with thinness is erasing body positivity and real, authentic bodies.
Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback